Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of August 2022, specifically reporting on a corporate event dated August 3, 2022. The filing details the termination of a strategic partnership with Bristol-Myers Squibb Company (BMS).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on the legal termination of a collaboration agreement.
Material Changes
- Termination of Agreement: Compugen and BMS entered into a letter agreement terminating the Master Clinical Trial Collaboration Agreement (CTCA) originally dated October 10, 2018.
- Loss of Rights: The termination includes the cessation of the right of first negotiation and the exclusivity rights previously granted to BMS under the CTCA.
- Wind-Down Activities: The parties agreed to use reasonable efforts to wind down activities related to two specific studies:
- The dual combination study of COM701 with nivolumab.
- The triple combination study of COM701 with nivolumab and BMS's investigational anti-TIGIT antibody (BMS-986207).
- Oversight: A sub-team comprising members from both parties will be created to oversee the wind-down process.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of general risks beyond the immediate impact of the terminated collaboration. The primary contingency noted is the operational wind-down of the specified clinical studies.
Investor Verification Checklist
- Verify the specific financial impact of the CTCA termination on Compugen's future revenue projections and R&D expenses.
- Confirm the status of the COM701 program and whether Compugen retains rights to pursue the dual and triple combination studies independently or with new partners.
- Review the terms of the wind-down agreement to understand any potential liabilities or remaining obligations to BMS.
- Assess the strategic implications of losing the exclusivity and right of first negotiation with BMS for Compugen's pipeline development.